Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis
- 9 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (10), 2726-2729
- https://doi.org/10.1093/cid/ciaa502
Abstract
This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG ≥10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.Keywords
Funding Information
- Instituto de Salud Carlos III (PI14/01094, PI14-01581, PI14CIII/00011)
- Spanish AIDS Research (RD16/0025/0017, RD16/0025/0018)
- ISCIII-Subdirección General de Evaluacion and European Funding for Regional Development
This publication has 8 references indexed in Scilit:
- Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective studyJournal of Infection, 2020
- Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated CirrhosisGastroenterology, 2017
- Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertensionJournal of Hepatology, 2016
- Expanding consensus in portal hypertensionJournal of Hepatology, 2015
- Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevanceJournal of Hepatology, 2014
- Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated CirrhosisGastroenterology, 2007
- Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD EraHepatology, 2005
- The hepatic venous pressure gradient: Anything worth doing should be done rightHepatology, 2004